NCT00622830View on ClinicalTrials.gov

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Atherosclerosis

Interventions

DRUG

SB-480848 (Darapladib)

Trial Locations (1)

305-0856

GSK Investigational Site, Ibaraki

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00622830 - Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects- | Biotech Hunter | Biotech Hunter